Journal of Cardiac Failure
Volume 14, Issue 6 , Pages 497-507, August 2008

Psychometric Testing of the MDASI-HF: A Symptom Assessment Instrument for Patients With Cancer and Concurrent Heart Failure

  • Anecita Fadol, PhD, RN, FNP

      Affiliations

    • Department of Cardiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX
    • Corresponding Author InformationReprint requests: Anecita Fadol, RN, PhD, and Daniel J. Lenihan, MD, Department of Cardiology – 449, 1515 Holcombe Blvd, Houston, TX 77030.
  • ,
  • Tito Mendoza, PhD

      Affiliations

    • Department of Symptoms Research, The University of Texas M.D. Anderson Cancer Center, Houston, TX
  • ,
  • Ibrahima Gning, MPH, DRPH(C)

      Affiliations

    • Department of Symptoms Research, The University of Texas M.D. Anderson Cancer Center, Houston, TX
  • ,
  • Jeanette Kernicki, PhD, RN

      Affiliations

    • Texas Woman's University, Houston, TX
  • ,
  • Lene Symes, PhD, RN

      Affiliations

    • Texas Woman's University, Houston, TX
  • ,
  • Charles S. Cleeland, PhD

      Affiliations

    • Department of Symptoms Research, The University of Texas M.D. Anderson Cancer Center, Houston, TX
  • ,
  • Daniel Lenihan, MD

      Affiliations

    • Department of Cardiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX

Received 15 August 2007; received in revised form 22 January 2008; accepted 28 January 2008. published online 07 April 2008.

Abstract 

Background

The debilitating symptoms of cancer and heart failure (HF) can adversely affect the patient's quality of life. This study evaluated the psychometric properties of the MD Anderson Symptom Inventory – Heart Failure (MDASI-HF), a 27-item self-report assessment instrument for patients with cancer and concurrent HF.

Methods and Results

Psychometric testing used data from 156 patients (age 63.3 ± 13.2 years, 56% male) with a diagnosis of cancer and HF receiving care in a major cancer center. Reliability of the MDASI-HF for the 13 symptoms (α = 0.89), 8 HF-specific items (α = 0.83), and interference items (α = 0.92) was high. Criterion-related validity with the Eastern Cooperative Oncology Group performance scale (r = 0.63) and the New York Heart Association classification (r = 0.65) were statistically significant, P = .01. Construct validity supported two constructs for the additional HF specific items: covert HF factor and overt HF factor.

Conclusion

The MDASI-HF is a valid and reliable instrument for symptom assessment in patients with cancer and HF. This instrument can be used to identify symptom occurrence and enhance the provider's understanding of the prevalence and severity of symptoms from the patient's perspective.

Key Words: Heart Failure, cancer, instrument, symptom assessment

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1071-9164(08)00040-7

doi:10.1016/j.cardfail.2008.01.012

Journal of Cardiac Failure
Volume 14, Issue 6 , Pages 497-507, August 2008